# Mahanine (Murraya koenigii / Micromelum minutum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/mahanine-murraya-koenigii-micromelum-minutum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Micromelum minutum alkaloid, Curry leaf alkaloid, Murraya koenigii carbazole, Mahanine (Murraya koenigii carbazole alkaloid), Mahanine (Murraya koenigii / Clausena species alkaloid), Mahanine-enriched fraction (MEF), Mahanine (from Murraya koenigii / Micromelum minutum), Mahanine carbazole alkaloid

## Overview

Mahanine is a carbazole alkaloid that induces apoptosis in cancer cells through [mitochondrial](/ingredients/condition/energy) membrane disruption, cytochrome c release, and caspase-3/9 activation, while also inhibiting topoisomerase I and the mTORC1/2 pathway. In preclinical models, concentrations of 7–9 µM reduce cellular ATP to 40–60% of controls in leukemia cells, and a mahanine-enriched fraction (MEF) demonstrates 31% greater oral bioavailability in rats compared to the purified compound alone.

## Health Benefits

- **Anticancer / Pro-apoptotic Activity**: Mahanine selectively triggers the intrinsic [mitochondrial](/ingredients/condition/energy) apoptosis pathway in multiple cancer cell lines, including leukemia (U937), glioblastoma, ovarian, breast, colon, and cervical cancer cells, by reducing mitochondrial membrane potential and activating caspase-3 and caspase-9 at low micromolar concentrations (7–9 µM).
- **Topoisomerase I Inhibition**: Mahanine binds the DNA minor groove and inhibits topoisomerase I, an enzyme critical for DNA replication and transcription in rapidly dividing cells, thereby interfering with cell cycle progression in cancer cells without the same degree of effect on quiescent normal cells.
- **mTOR Pathway Suppression**: In glioblastoma models, mahanine inhibits both mTORC1 and mTORC2 complexes while downregulating the pro-survival kinase pAkt, disrupting nutrient-sensing and proliferative signaling cascades that are commonly hyperactivated in malignant tumors.
- **[Immunomodulatory](/ingredients/condition/immune-support) Effects**: Mahanine has demonstrated immunomodulatory activity in preclinical contexts, modulating inflammatory signaling pathways consistent with the broader pharmacological profile of carbazole alkaloids from Murraya koenigii, which are used in Ayurvedic medicine for [anti-inflammatory](/ingredients/condition/inflammation) indications.
- **Anti-nociceptive (Analgesic) Properties**: Preclinical data support antinociceptive activity for mahanine, aligning with the traditional use of Murraya koenigii preparations for pain-related conditions, though the precise receptor-level mechanisms underlying this effect require further characterization.
- **[Autophagy](/ingredients/condition/longevity) and Anoikis Modulation**: In ovarian cancer models, mahanine promotes LC3-mediated anoikis while simultaneously inhibiting cytoprotective autophagy, a dual mechanism that may limit cancer cell survival under conditions of anchorage loss and metabolic stress.
- **Selective Pro-oxidant Activity**: Mahanine acts as a pro-oxidant specifically within cancer cells, generating [reactive oxygen species](/ingredients/condition/antioxidant) that overwhelm malignant cell antioxidant defenses, while sparing normal cell types including neonatal skeletal muscle cells, cardiomyocytes, and hepatocytes in preclinical assays.

## Mechanism of Action

Mahanine initiates apoptosis predominantly through the intrinsic [mitochondrial](/ingredients/condition/energy) pathway: it disrupts mitochondrial membrane permeability, triggering cytochrome c release into the cytosol, which activates the apoptosome complex and downstream executioner caspases (caspase-3 and caspase-9), ultimately reducing cellular ATP to 40–60% of control values at 7–9 µM in U937 leukemia cells within 6–12 hours; pretreatment with cyclosporine A, a mitochondrial permeability transition pore blocker, abrogates these effects, confirming mitochondrial centrality. At the genomic level, mahanine acts as a DNA minor groove binder and topoisomerase I inhibitor, impeding DNA strand-break re-ligation during replication and thereby inducing genotoxic stress selectively in proliferating cells. It downregulates anti-apoptotic proteins Bcl-xL and phospho-Akt while suppressing both mTORC1 and mTORC2 in glioblastoma, disrupting integrated survival and metabolic signaling. In ovarian cancer contexts, it concurrently promotes LC3-dependent anoikis and suppresses protective [autophagy](/ingredients/condition/longevity), while functioning as a cancer cell-selective pro-oxidant that spares differentiated normal cell populations.

## Clinical Summary

No human clinical trials investigating mahanine as a therapeutic or supplemental agent have been conducted or reported in the accessible scientific literature, making a formal clinical summary impossible at this time. Available preclinical evidence demonstrates consistent pro-apoptotic and antiproliferative effects across diverse cancer cell lines at low micromolar concentrations and tumor reduction in a rat mammary cancer model, but effect sizes and confidence intervals from animal studies have not been fully published. The absence of Phase I dose-escalation studies means that safe human dosing ranges, pharmacokinetic parameters in humans, and clinically relevant efficacy endpoints remain entirely unestablished. Confidence in translating existing preclinical findings to human benefit is currently low, and the compound should be regarded as an early-stage research candidate rather than a clinically validated intervention.

## Nutritional Profile

Mahanine is a pure alkaloid compound (molecular formula C₁₉H₁₇NO, molecular weight approximately 275.35 g/mol) and does not constitute a nutritional source of macronutrients, vitamins, or minerals in any meaningful dietary quantity. As a secondary metabolite present in trace amounts within Murraya koenigii leaves, it co-occurs in the leaf matrix alongside other carbazole alkaloids (mahanimbine, koenimbine, isomahanine, girinimbine), flavonoids, vitamins (notably vitamin A, B-complex, C), iron, calcium, and dietary fiber that characterize curry leaf nutritional composition, though these are attributable to the whole leaf rather than to mahanine itself. The compound's bioavailability when consumed as part of whole curry leaves is unknown and almost certainly far below the micromolar concentrations required for the pharmacological effects observed in cell culture. The MEF formulation achieves measurably higher systemic exposure in rats (31% above purified compound) due to matrix effects that likely slow absorption and reduce first-pass [metabolism](/ingredients/condition/weight-management), though human bioavailability data are absent.

## Dosage & Preparation

- **Purified Compound (Research Grade)**: Used exclusively in laboratory and preclinical settings; in vitro effective concentrations range from 7–9 µM; no human dose equivalent established.
- **Mahanine-Enriched Fraction (MEF)**: An optimized extract from Murraya koenigii leaves produced via methanol or ethyl acetate extraction followed by fractionation; demonstrates 31% superior oral bioavailability in rats versus purified mahanine; no human dosage established.
- **Crude Leaf Extract**: Methanol or ethyl acetate extracts of M. koenigii leaves contain quantifiable mahanine alongside related carbazole alkaloids; used in research settings; not commercially standardized for mahanine content.
- **Traditional Dietary Form**: Fresh or dried curry leaves (M. koenigii) consumed as food or decoction in Ayurvedic practice; mahanine content is not standardized and is present in trace, unquantified amounts relative to therapeutic concentrations used experimentally.
- **Stability Note**: Mahanine and MEF are stable across pH 1–10 for approximately 3 hours, supporting theoretical oral administration, though no human oral dosing regimen has been validated.
- **Standardization**: No commercial supplement standard or certificate of analysis benchmark for mahanine percentage currently exists in the nutraceutical market.

## Safety & Drug Interactions

Preclinical safety data are limited but initially encouraging: mahanine shows no acute toxicity in mice across one month of treatment, and in vitro studies consistently demonstrate selectivity for cancer cells over normal cell types including hepatocytes, cardiomyocytes, and neonatal skeletal muscle cells, suggesting a potential therapeutic window. No human safety data, adverse event profiles, maximum tolerated doses, or drug interaction studies exist, making it impossible to characterize a human safety profile with confidence. A mechanistically important interaction is the reversal of mahanine's [mitochondrial](/ingredients/condition/energy) effects by cyclosporine A in vitro, suggesting potential pharmacodynamic interaction with agents that modulate mitochondrial permeability transition pores, including immunosuppressants; synergistic anticancer effects have also been noted with approved drugs in colon and cervical cancer models, indicating possible pharmacodynamic drug interactions requiring careful study before any co-administration. Mahanine is not recommended for use in pregnancy, lactation, or pediatric populations given the complete absence of human safety data, and individuals taking immunosuppressive or anticancer medications should avoid unsupervised use of concentrated extracts or supplements claiming mahanine content.

## Scientific Research

The current body of evidence for mahanine consists entirely of in vitro cell line studies and preclinical rodent models, with zero registered or completed human clinical trials as of the available literature; this places the compound at an early translational research stage. In vitro studies have characterized apoptotic mechanisms across multiple cancer cell lines (U937 leukemia, glioblastoma, ovarian, breast, colon, cervical), typically employing concentrations of 7–9 µM, and have established selectivity for malignant over normal cell types across multiple independent experimental systems. Preclinical in vivo data include a rat mammary tumor model demonstrating tumor reduction attributed to breast cancer stem cell suppression, and a mouse safety study showing no acute toxicity over one month of treatment, though specific sample sizes, effect magnitudes, and statistical parameters are not fully detailed in available sources. The pharmacokinetic finding that a mahanine-enriched fraction (MEF) achieves 31% higher bioavailability than purified mahanine in rats, with compound stability across pH 1–10 for approximately three hours, provides mechanistically useful data for eventual formulation development, but extrapolation to human pharmacokinetics remains premature.

## Historical & Cultural Context

Murraya koenigii, the primary botanical source of mahanine, has a centuries-long history of use in Ayurvedic medicine across the Indian subcontinent, where its leaves were employed in preparations for [antiviral](/ingredients/condition/immune-support), [anti-inflammatory](/ingredients/condition/inflammation), [antioxidant](/ingredients/condition/antioxidant), antidiabetic, and antitumor indications, with the plant referenced in classical Sanskrit medical texts as well as folk traditions throughout South and Southeast Asia. The curry leaf tree holds cultural significance beyond medicine, serving as an essential culinary ingredient in South Indian, Sri Lankan, and Southeast Asian cuisines, where leaves are routinely added to cooking — a practice that incidentally provides low-level dietary exposure to mahanine and related carbazole alkaloids. Traditional preparations did not isolate mahanine specifically but rather employed whole-leaf decoctions, pastes, or infusions, attributing therapeutic effects to the plant holistically rather than to individual alkaloids. The scientific isolation and characterization of mahanine as a discrete bioactive carbazole alkaloid is a product of modern phytochemical research, with significant investigation beginning in the latter decades of the twentieth century and accelerating in the twenty-first century alongside growing interest in plant-derived anticancer compounds.

## Synergistic Combinations

In preclinical colon and cervical cancer models, mahanine demonstrates synergistic antiproliferative activity when combined with approved chemotherapeutic agents, with the combination producing greater cancer cell death than either agent alone, likely through complementary apoptotic pathway engagement — though the specific drug partners and precise mechanistic basis of synergy have not been fully delineated in publicly available data. The co-occurrence of mahanine with structurally related carbazole alkaloids (mahanimbine, koenimbine, girinimbine) in Murraya koenigii whole-leaf extracts may produce additive or synergistic effects within the MEF fraction compared to isolated mahanine, which may partly explain the superior bioavailability and activity profile of the enriched fraction. Based on mechanism, combining mahanine with agents that promote [oxidative stress](/ingredients/condition/antioxidant) in cancer cells or inhibit Bcl-2 family anti-apoptotic proteins represents a theoretically rational synergistic strategy, but no validated human-relevant combination protocols have been established.

## Frequently Asked Questions

### What is mahanine and where does it come from?

Mahanine is a naturally occurring carbazole alkaloid — a nitrogen-containing bicyclic aromatic compound — found primarily in the leaves of Murraya koenigii (curry leaf tree) and Micromelum minutum, both subtropical and tropical plants native to South and Southeast Asia. It is one of several related carbazole alkaloids in curry leaf, including mahanimbine and koenimbine, and is extractable from dried or fresh leaves using polar solvents such as methanol or ethyl acetate. It is not currently available as a standalone commercial supplement.

### How does mahanine kill cancer cells?

Mahanine targets the mitochondria of cancer cells, disrupting membrane permeability and triggering the release of cytochrome c into the cytosol, which activates the executioner caspases (caspase-3 and caspase-9) that dismantle the cell from within — a process known as intrinsic apoptosis. It simultaneously inhibits topoisomerase I by binding the DNA minor groove, downregulates the survival proteins Bcl-xL and phospho-Akt, and suppresses both mTORC1 and mTORC2 signaling. These combined effects reduce cellular ATP to 40–60% of control levels at concentrations of 7–9 µM and have been demonstrated across leukemia, glioblastoma, ovarian, and breast cancer cell lines in laboratory studies.

### Are there human clinical trials on mahanine?

No human clinical trials on mahanine have been conducted or reported as of the current available scientific literature; all evidence to date is derived from in vitro cell line experiments and preclinical rodent studies. While these preclinical findings are mechanistically compelling — showing tumor reduction in rat mammary cancer models and no acute toxicity in mice over one month — they cannot be directly extrapolated to human safety or efficacy. Mahanine must be considered an early-stage research compound rather than a clinically validated therapeutic agent.

### What is a mahanine-enriched fraction (MEF) and is it better than pure mahanine?

A mahanine-enriched fraction (MEF) is an optimized plant extract from Murraya koenigii leaves processed to maximize mahanine content relative to other alkaloids, produced through sequential methanol or ethyl acetate extraction and fractionation steps. In rat pharmacokinetic studies, MEF achieves 31% higher systemic bioavailability compared to an equivalent dose of purified mahanine, likely because the natural plant matrix modulates absorption or reduces first-pass metabolism. MEF also maintains stability across a broad pH range (1–10) for approximately three hours, making it theoretically suitable for oral delivery, though no human bioavailability or dosing data are yet available.

### Is mahanine safe to take as a supplement?

Mahanine is not currently available as a standardized commercial supplement, and no established safe human dose exists. Preclinical data suggest selectivity for cancer cells over normal cell types (hepatocytes, cardiomyocytes, skeletal muscle cells) and no acute toxicity in mice over one month, which is reassuring at early stages. However, the complete absence of human pharmacokinetic, safety, and toxicology data means that no safety assurances can be made; individuals on immunosuppressive therapy (e.g., cyclosporine A) or anticancer medications face particular unknown risks, and use during pregnancy or lactation cannot be supported by current evidence.

### What is the difference between mahanine from Murraya koenigii versus Micromelum minutum?

Both Murraya koenigii (curry leaf tree) and Micromelum minutum are natural sources of mahanine, but they differ in alkaloid composition and concentration levels. Murraya koenigii is the more commonly studied and traditionally used source, particularly in Ayurvedic medicine, while Micromelum minutum represents an alternative botanical source with potentially similar mahanine content. The choice between sources may affect overall phytochemical profile and bioactivity beyond just mahanine concentration.

### Does mahanine interact with chemotherapy drugs or cancer medications?

Mahanine works through topoisomerase I inhibition and mitochondrial apoptosis pathways, which overlap with some conventional chemotherapy mechanisms, raising theoretical interaction potential. Limited human data exists on mahanine interactions with specific cancer medications, so concurrent use with prescription chemotherapy should only be undertaken under medical supervision. Those undergoing active cancer treatment should consult their oncologist before supplementing with mahanine to avoid potential conflicts with their treatment protocol.

### What concentration of mahanine is needed to achieve the anticancer effects seen in research?

In-vitro studies demonstrate mahanine's pro-apoptotic effects at low micromolar concentrations (7–9 µM) against various cancer cell lines including leukemia, glioblastoma, and breast cancer cells. However, translating these laboratory concentrations to effective supplement dosing in humans remains unclear due to limited pharmacokinetic and bioavailability data in clinical populations. The gap between cell-culture effective doses and achievable human serum levels is a major reason why human clinical trials are still needed to determine practical supplemental dosing.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*